Michael E Goldberg

List of Publications by Year
in descending order

11 papers	1,701 citations	1040056 9 h-index	1372567 10 g-index
12 all docs	12 docs citations	12 times ranked	3572 citing authors

#	Article	IF	Citations
1	*STK11/LKB1* Mutations and PD-1 Inhibitor Resistance in *KRAS*-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	9.4	1,108
2	Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer, 2017, 108, 228-231.	2.0	125
3	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	7.0	107
4	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
5	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. Cancer Research, 2017, 77, 2464-2475.	0.9	93
6	Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. Genome Medicine, 2017, 9, 16.	8.2	50
7	The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. PLoS ONE, 2020, 15, e0231999.	2.5	36
8	Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. Cancer Research, 2017, 77, 6313-6320.	0.9	22
9	Mutational Signatures of Replication Timing and Epigenetic Modification Persist through the Global Divergence of Mutation Spectra across the Great Ape Phylogeny. Genome Biology and Evolution, 2022, 14, .	2.5	21
10	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS ONE, 2018, 13, e0208097.	2.5	17
11	Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. Molecular Cancer Therapeutics, 2020, 19, 292-303.	4.1	9